Company news
Shuttle Pharmaceuticals Holdings, Inc. news in 2023
Shuttle Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2023, newest first.
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
December 10, 2023
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
November 13, 2023
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
October 30, 2023
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
September 24, 2023
Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform
September 10, 2023
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
August 14, 2023
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial
August 2, 2023
Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
May 25, 2023
Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates
March 21, 2023
Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update
March 14, 2023
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
March 8, 2023
Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities
February 22, 2023
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023
January 16, 2023
Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants
January 11, 2023
Decks in 2023
- Investor Presentation (March 2023)
Investor deck · 20 slides · Mar 22, 2023